A new advancement in the treatment of metastatic triple-negative breast cancer

Metastatic triple-negative breast cancer (mTNBC) represents a major challenge for healthcare professionals. Characterized by high aggressiveness and resistance to conventional treatments, its prognosis is often less favorable than other types of breast cancer. This underscores the critical need for therapeutic innovations. Sacituzumab govitecan (SG), a newly approved antibody-drug conjugate, specifically targets TROP2, a protein overexpressed in mTNBC. This study aims to evaluate and analyze the efficacy and tolerability of this innovative treatment in patients who have already undergone multiple lines of therapy.

This study analyzed the efficacy and safety of SG in 132 patients with mTNBC who had received at least two prior lines of treatment. Data were collected retrospectively from 16 cancer treatment centers in the United Kingdom. SG's effects were measured using parameters such as survival rates and adverse events.

Key findings of the study are as follows:

The results of this study provide robust evidence of the clinical efficacy of SG in heavily pretreated mTNBC patients. However, notable toxicities require careful, individualized dose and side effect management to sustain treatment in this population.

These findings establish a solid foundation for further studies, especially on the effects of SG in patients with brain metastases. A broader evaluation of its use in combination with other agents could also improve treatment for these critically ill patients.